Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute

Bone Marrow Transplantation

Volumn 43, Issue 4, 2009, Pages 315-321

  Hou, H A ^a   Yao, M ^a   Tang, J L ^a   Chen, Y K ^a   Ko, B S ^a   Huang, S Y ^a   Tien, H F ^a   Chang, H H ^a   Lu, M Y ^a   Lin, T T ^a   Lin, K H ^a   Hsiao, C H ^a   Lin, C W ^a   Chen, Y C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; RITUXIMAB; THYMOCYTE ANTIBODY; VIRUS ANTIGEN; VIRUS RNA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; OUTCOME ASSESSMENT; POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LUNG DISEASES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61449101655     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.325     Document Type: Article

References (33)

1. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173-192.
2. Cohen JI. Epstein0-Barr virus lymphoproliferative disease associated with acquired immunode.ciency. Medicine (Baltimore) 1991; 70 137-160.
3. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461-472.
4. Blazar B, Patarroyo M, Klein E, Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med 1980; 151: 614-627.
5. Pearson GR, Orr TW. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. J Natl Cancer Inst 1976; 56: 485-488.
6. Wallace LE, Rickinson AB, Rowe M, Epstein MA. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982; 297: 413-415.
7. Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251-258.
8. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71 1234-1243.
9. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784-789.
10. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED et al Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
11. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94 2208-2216.
12. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA et al Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
13. d'Amore ES, Manivel JC, Gajl-Peczalska KJ, Litz CE, Copenhaver CM, Shapiro RS et al. B-cell lymphoproliferative disorders after bone marrow transplant. An analysis of ten cases with emphasis on Epstein-Barr virus detection by in situ hybridization. Cancer 1991; 68: 1285-1295.
14. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
15. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
16. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229-239.
17. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood 1998; 91 1833-1844.
18. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
19. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1 583-587.
20. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A et al. Chimaeric anti-CD20monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112-118.
21. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113-116.
22. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002; 118: 728-740.
23. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC et al Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576.
24. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P et al. Efficacy and safety of rituximab in Bcell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
25. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906.
26. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998; 92: 3137-3147.
27. Hoshino Y, Kimura H, Kuzushima K, Tsurumi T, Nemoto K, Kikuta A et al Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load. Bone Marrow Transplant 2000; 26: 199-201.
28. Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E et al The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224-233.
29. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98-103.
30. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165-1171.
31. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981.
32. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBVspecific cytotoxic T cells. Blood 2000; 95: 807-814.
33. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-978.